Keith J. Gray’s conviction underscores rising enforcement and audit risk as Medicare spending shifts toward high-cost genetic testing.
A federal jury in Dallas has convicted Texas laboratory owner and former NFL player Keith J. Gray for orchestrating a $328 million Medicare fraud scheme tied to unnecessary cardiovascular genetic testing. Gray, age 39, owned and operated Axis Professional Labs LLC and Kingdom Health Laboratory LLC, which billed Medicare for tests that were not medically necessary, according to the US Department of Justice (DOJ).
The jury convicted Gray on multiple counts, including conspiracy to defraud the United States, violations of the Anti-Kickback Statute, and money laundering. He now faces up to 10 years in prison for each count, with sentencing to be determined by a federal judge.
Gray briefly pursued a professional football career after playing at the University of Connecticut, signing as an undrafted free agent with the Carolina Panthers in 2009 and later spending time on the Indianapolis Colts practice squad, though he never appeared in a regular-season NFL game, according to Fox Sports.
Kickbacks and Sham Contracts Drove Genetic Testing Fraud
According to evidence presented at trial, Gray paid illegal kickbacks to marketers in exchange for Medicare beneficiaries’ DNA samples, personal information, and signed physician orders, the DOJ said. These marketers relied on aggressive telemarketing tactics and a practice known as “doctor chasing,” in which they identified patients’ primary care physicians and pressured them to approve genetic testing orders, prosecutors noted. In many cases, these approvals were based on pre-screening conducted by non-medical personnel rather than legitimate clinical evaluations.
To conceal the scheme, Gray used sham contracts and falsified invoices that were labeled as payments for marketing services, software, or loans. In reality, these payments were structured to match per-sample kickbacks. “Evidence at trial included text messages between Gray and his co-conspirator becoming giddy over the amount of money they were making from Medicare,” the DOJ noted.
Photo credit: NFL Photos
The two laboratories billed Medicare approximately $328 million in fraudulent claims, resulting in about $54 million in payments. Gray used some of these proceeds to purchase luxury vehicles, including high-end trucks and SUVs, as part of efforts to launder the illicit funds.
The case was investigated by multiple federal and state agencies, including the FBI, HHS Office of Inspector General, Texas Medicaid Fraud Control Unit, and the VA Office of Inspector General, underscoring ongoing enforcement efforts targeting fraud in clinical laboratory testing.
The Gray case underscores exactly the risk highlighted in a recent article from The Dark Report on a report from the Department of Health and Human Services’ Office of Inspector General that found genetic tests make up just 5% of volume but now drive 43% of Medicare Part B lab spending. As Medicare spending becomes increasingly concentrated in high-cost genetic testing, enforcement agencies are intensifying scrutiny around medical necessity and billing practices.
Gray’s $328 million fraud scheme—built on kickbacks, questionable ordering practices, and medically unnecessary tests—reflects the same misbehaviors regulators are now targeting. Because of fraud cases such as this, honest laboratories must make greater effort to strengthen compliance, validate ordering patterns, and prepare for heightened audits in the molecular diagnostics space.
Strategies to mitigate diagnostic testing fraud will be a key focus at the 31st Annual Executive War College taking place in New Orleans April 28-29.
Johns Hopkins researchers show that measuring DNA methylation variability can improve early cancer detection accuracy and strengthen liquid biopsy performance across diverse patient populations.
Researchers at Johns Hopkins Kimmel Cancer Center are advancing a new approach to liquid biopsy that could improve early cancer detection by focusing on variability in DNA methylation patterns—rather than absolute levels—offering a potentially more reliable biomarker across diverse patient populations.
Dark Daily’s sibling publication Today’s Clinical Labreported that the liquid biopsy market is expected to increase by approximately 20% between 2022 and 2032, noting early cancer detection as a driver of the increase.
The method introduces a novel metric called the Epigenetic Instability Index (EII), designed to measure random variation, or “stochasticity,” in DNA methylation. In a proof-of-concept study published in Clinical Cancer Research, the approach demonstrated strong performance in distinguishing patients with early-stage cancers from healthy individuals.
“This is the first study where we are trying to really implement measuring that variation, or stochasticity, into a diagnostic tool,” said lead author Hariharan Easwaran, PhD. “We immediately found that measuring DNA methylation variation performs better than just measuring DNA methylation by itself.”
Model Targets Methylation Variability to Improve Multi-Cancer Detection
Traditional methylation-based liquid biopsies typically rely on detecting fixed changes at specific genomic sites. However, those tests are often developed using narrow patient cohorts and can struggle to generalize across broader populations. By contrast, the EII approach aims to capture a more universal biological signal tied to early tumor development.
To build the model, researchers analyzed more than 2,000 publicly available DNA methylation samples and identified 269 genomic regions (CpG islands) that capture the majority of methylation variability across cancer types.
“We identified specific genomic regions that tend to be the most variable in DNA methylation marks during cancer,” said first author Sara-Jayne Thursby, a postdoctoral researcher in Easwaran’s lab. “In cell-free DNA in the blood, that variability shouldn’t be high, but if it is, it is indicative of a developing cancerous phenotype.”
Using these regions, the team trained a machine learning model that demonstrated high accuracy across multiple cancers. In lung adenocarcinoma, the test detected stage 1A disease with 81% sensitivity at 95% specificity. For early-stage breast cancer, sensitivity reached approximately 68% at the same specificity level. The tool also showed potential utility in colon, pancreatic, brain, and prostate cancers.
Researchers say the findings support the idea that epigenetic instability may be an early hallmark of cancer progression.
“We hypothesize that early-stage tumors and precancerous lesions that exhibit high degrees of methylation variation… may be more resistant to intrinsic cancer-protective mechanisms and progress more rapidly,” said co-lead author Thomas Pisanic, PhD.
Looking ahead, the team plans to further validate the EII in larger clinical studies and position it as a complementary tool alongside existing screening methods. Easwaran noted that the test could serve as a “secondary triaging measure,” helping clinicians determine whether follow-up procedures—such as biopsies—are necessary after inconclusive or false-positive screening results.
For clinical laboratories, the approach signals a growing shift toward more nuanced, data-driven biomarkers that may improve early detection while reducing unnecessary procedures.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
With genetic test spending under the microscope, CMS is asking labs to help shape future anti-fraud rules—before formal proposals are drafted.
Clinical laboratory leaders have a narrowing window to influence a major new federal anti-fraud initiative, as the Centers for Medicare and Medicaid Services (CMS) closes its March 30 comment period on its “CRUSH” request for information (RFI).
Published Feb. 27, the CRUSH (Comprehensive Regulations to Uncover Suspicious Healthcare) initiative signals CMS’s intent to pursue broader regulatory changes aimed at strengthening program integrity across Medicare, Medicaid, and Medicare Advantage. For laboratories, the RFI offers an early opportunity to weigh in before formal rulemaking begins.
CMS Targets Genetic Testing Spend, MolDX Oversight, and Advanced Analytics in Fraud Crackdown
A central focus is fraud tied to clinical diagnostic testing, particularly genetic and molecular assays. CMS cited recent federal data showing that while genetic tests accounted for just 5% of Medicare Part B test volume in 2024, they represented 43% of total lab spending—approximately $3.6 billion. The agency also pointed to ongoing enforcement actions and fraud alerts tied to laboratory testing as justification for heightened scrutiny.
Photo credit: Wikimedia Commons
CMS is asking laboratories and other stakeholders to identify what new regulatory authorities, analytics tools, and data-driven approaches could improve detection and prevention of fraudulent billing. The agency’s questions suggest interest in expanding pre- and post-payment review, strengthening data analytics, and accelerating fraud detection earlier in the reimbursement claims lifecycle.
Another key issue for labs is CMS’s examination of the Molecular Diagnostic Services (MolDX) program. The agency is seeking feedback on whether MolDX registration reduces fraud risk and why some payers require participation even outside MolDX jurisdictions—raising the possibility of broader adoption or new requirements tied to molecular test oversight.
For laboratory executives, compliance leaders, and revenue cycle teams, the implications are significant. The RFI signals where CMS may tighten oversight next, particularly for high-cost, high-complexity testing. Policies affecting enrollment, documentation, payment review, and test validation could follow.
With the March 30 deadline approaching, laboratories still have time to submit operational insights and data to help shape future regulations.
From MD Anderson’s workforce pillars to NYU Langone’s digital pathology overhaul, the 2026 Executive War College speaker spotlight highlights the “boots-on-the-ground” experts set to reveal how labs can navigate reimbursement pressure and regulatory shifts this April in New Orleans.
As clinical laboratories face a “perfect storm” of reimbursement pressure, workforce shortages, and shifting regulatory mandates, the upcoming Executive War College on Diagnostics, Clinical Laboratory, and Pathology Management (April 28-29, 2026) has released its first wave of speaker spotlights. The 2026 agenda will focus on “early-adopter” case studies that demonstrate how labs can stop merely keeping pace to instead set new standards in innovation.
Speaker Highlights: Driving Financial and Operational Resilience
Among the key thought leaders taking the podium are experts focused on the high-stakes intersection of clinical quality, workforce stability, and bottom-line profitability.
Walter McAndrew, MB(ASCP), SSGB, molecular diagnostics laboratory manager at MD Anderson Cancer Center
McAndrew will detail a high-impact case study on workforce stability. In an era of rampant burnout and reliance on expensive traveler staff, McAndrew will demonstrate how MD Anderson re-engineered its molecular operations to better drive measurable quality while simultaneously reducing costs.
Jonathan Burgart, director of US marketing at Abbott Core Diagnostics
Burgart is set to challenge the “cost-center mindset” that plagues many hospital-based laboratories. His session will provide a strategic framework for hospital executives to use excess capacity and operational data to improve operating margins and net income.
Christina Olesnycky and Syed T. Hoda, MD, NYU Langone Health
Leading the shift toward high-volume automation, the two speakers will share the roadmap NYU Langone used to achieve a full digital pathology workflow in just one year. Their presentation will highlight how pathology at scale accelerates diagnosis and provides a necessary foundation for AI-enabled innovation.
Stefanie Davidson, laboratory director at Foundation Health
Davidson will share proven workforce strategies that help laboratories break their dependency on temporary staffing and achieve long-term operational stability.
Executive War College 2025. Photo credit: EWC
Why It Matters for Lab Leaders
The 2026 program arrives at a critical strategic tipping point as laboratories move from a period of regulatory uncertainty into a year of mandatory execution. With the expiration of legislative moratoriums on PAMA reporting and the shift toward a post-LDT ruling reality, the margin for operational error has effectively disappeared. This year’s sessions move beyond high-level theory to address the hurdles of 2026: navigating the “regulatory cliff,” defending shrinking margins against a surge in federal audit activity, and transitioning AI and digital pathology from expensive pilot projects into essential, everyday workflows.
“The laboratory has the potential to reframe its role in the healthcare system,” noted Burgart, emphasizing that this year’s sessions will provide the specific financial and operational blueprints required to turn regulatory challenges into a sustainable competitive advantage.
About the Event
The 31st Annual Executive War College will be held at the Hyatt Regency New Orleans. It remains the largest gathering of lab and pathology leaders focused exclusively on the business and management of diagnostic medicine.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
Experts share strategies to help clinical laboratories prepare for disruptions, protect samples, and maintain testing operations during unexpected crises.
Laboratory crises rarely announce themselves in advance. They may begin with an after-hours phone call, a freezer alarm that fails to trigger, or a system outage that forces leaders to act before all the facts are known. In clinical laboratories, a crisis is not limited to catastrophic accidents. It can include any event that disrupts regulated operations or threatens staff safety—from equipment failures and power outages to cyber incidents, water damage, or supply chain breakdowns. For laboratory leaders, the central question is not whether disruptions will occur, but whether the lab is prepared when routine safeguards fail.
Effective preparation begins by identifying where failures could cascade across laboratory operations. Many labs track hazards, but fewer examine how a single breakdown could ripple through staffing, equipment, utilities, vendors, and data systems.
Jason Nagy, PhD, MLS (ASCP), lab safety support coordinator for Sentara Health, recommended starting with the earliest point of failure and working backward to identify mitigation steps. In practice, this type of analysis often reveals a common issue: staff uncertainty during emergencies. Written procedures alone rarely prepare laboratorians to respond under pressure, making drills and scenario-based training essential. (Photo credit: Sentra Health)
Cross-training is another critical safeguard. When only a few individuals know how to manage spill responses, downtime procedures, or emergency shutdowns, those employees quickly become overwhelmed while others hesitate to act.
Systems, Communication, and Leadership
Infrastructure reliability is another major factor in crisis resilience. Critical systems—including alarm monitoring, backup power, and environmental controls—must be tested regularly to ensure they function when staff are offsite. Durnan noted that many laboratories discover alarm failures only after equipment losses occur, such as freezer systems that fail over a weekend without notifying staff.
Supply redundancy can also determine whether labs preserve irreplaceable materials. During a building flood that disrupted liquid nitrogen deliveries, Durnan’s lab avoided sample loss because a backup supply tank was already in place.
When disruptions occur, leadership coordination becomes essential. Nagy described how Sentara Health activates an incident command center during emergencies, bringing together couriers, receiving labs, and leadership to quickly coordinate decisions such as specimen rerouting and operational adjustments.
Even with preparation, uncertainty remains inevitable. Nagy emphasized the importance of contingency planning, noting that laboratories should always have multiple fallback strategies when normal workflows break down.
For clinical laboratory leaders, the broader takeaway is that resilience must be built into everyday operations. Training, infrastructure testing, cross-training, and well-defined communication structures help ensure laboratories can protect staff, preserve samples, and maintain testing services when unexpected disruptions occur.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
